pSivida Corp. (PSDV) Starts Presentation at LD Micro Conference

pSivida Corp. provides miniaturized, sustained-release drug delivery products. The company’s proprietary technologies enable the highly focused, long-term delivery of therapeutics. pSivida has developed three of the only four products approved by either the U.S. or EU for the long-term, sustained-released delivery of drug to treat chronic eye disease.  The company’s intellectual property portfolio consists of more than 150 issued patents in countries including the U.S., Europe, Japan, China and Australia. For more information, visit the company’s website at www.psivida.com.